We wi tink bɔt kansa tritmɛnt, wi kin tink wantɛm wantɛm bɔt tritmɛnt dɛn lɛk kemotɛrapi ɛn rediotɛrapi, nɔto so? Bɔt yu no se apat frɔm dɛn tin ya, wan nyu we de fɔ trit pipul dɛn we dɔn go bifo we go ebul fɔ yuz wi yon bɔdi in yon difens sistɛm fɔ fɛt di kansa sɛl dɛn? Na dat wi kin kɔl imyunotɛrapi.
So, fɔ tɔk am simpul wan, wetin na imyunotɛrapi?
Immunotherapy na tritmɛnt we de mek yu bɔdi in yon imyun sistɛm , ɔ ‘wek am’, fɔ ɛp am fɔ no, atak, ɛn pwɛl di bɔdi kansa sɛl dɛm. I tan lɛk se yu de tren yu yon difens fɔs fɔ fɛn ɛn pwɛl ɛnimi dɛn we ayd (kansa sɛl dɛn).
Naw, dɔktɔ dɛn kin yuz dis tritmɛnt mɔ fɔ triplɛ-negativ bɔdi kansa, we na wan kayn we we at fɔ trit. Dɛn kin yuz am bak fɔ mɛtastas brɔst kansa . pan tap dat, risach stil de go bifo pan di bεnεfit dεm we imyuno tεrapi de gi fכ כda kayn brεst kεnsar, lεk HER2-positiv εn ER-positiv.
Aw dis tritmɛnt de wok insay wi bɔdi?
Fɔ ɔndastand dis, lɛ wi tek wan smɔl ɛgzampul. Imajin se wi imyun sistɛm tan lɛk di polis dɛn na wi kɔntri. Di polis wok na fɔ no ɛn kech bad pipul ɛn tifman dɛn. Di sɛl dɛn we gɛt wɛlbɔdi ɛn di kansa sɛl dɛn na wi bɔdi gɛt spɛshal prɔtin dɛn na dɛn say. Wi kin kɔl dɛn antijen ya .
Bɔt kansa sɛl dɛn na tifman dɛn we rili kɔni. sכm kεnsar sεl dεm, bay we dεn de chenj di protin dεm we de na dεn sεf, de disgz dεn sεf εn sho di imyun sistεm, di polis, "A nכ bad, a na wan pan una." Dɔn di polis dɛn nɔ ebul fɔ no dis tifman. Immunotherapy de ya fɔ mek dis kɔni wok nɔ wok.
Dis tritmɛnt kin woke pan tu men we dɛn:
- Aktiv Imyun tεrapi dεm: Dis involv fכ gi yu כwn imyun sistεm spεshal ‘tren’. di imyun sistεm dεn tren fכ no spεsifi k mak dεm (antijen dεm) we dεn fכnshכn כnli pan kεnsar sεl dεm εn atak dεm nכmכ.
- Passive Immunotherapy: Dis kin min fɔ injɛkt wan spɛshal mɛrɛsin we dɛn mek na lab insay di bɔdi. Dis drɔg de wok lɛk ‘spɛshal fɔs’ yunit we de kam ɛp wi imyun sistɛm. Di mɛrɛsin kin go dairekt to di kansa sɛl dɛn ɛn i kin pul dɛn mask ɛn mek dɛn kɔmɔt na do.
Us kayn imyunotɛrapi drɔgs dɛn kin gi fɔ brɔst kansa?
Naw, tu men kayn mɛrɛsin dɛn de we dɛn dɔn gri fɔ yuz fɔ mɛn bɔdi kansa na di wɔl.
1. Pembrolizumab (Keytruda®): Dis na di mɛrɛsin we dɛn kin yuz mɔ. Dɛn kin gi am mɔ fɔ triplɛ-nɛgitiv brɔst kansa. Dis drɔg de wok bay we i de blok wan spɛshal prɔtin we di kansa sɛl dɛn de yuz fɔ ayd dɛnsɛf. dis kin mek di imyun sistεm ebul fכ no εn atak di kansa sεl dεm izi wan. Sɔntɛnde, dɛn kin gi dis mɛrɛsin bifo ɛn afta di ɔpreshɔn fɔ mek di kansa nɔ kam bak.
2. Dostarlimab (Jemperli®): Dɛn kin gi dis mɛrɛsin to pasɛnt dɛn we dɛn kansa dɔn skata afta ɔda tritmɛnt ɛn we gɛt spɛshal jenɛtik mak (tumor marker) na dɛn kansa sɛl.
De impɔtant tin na dat, dɛn tritmɛnt ya nɔr kin bi di sem fɔ ɔlman. Yu dɔktɔ go disayd if dis tritmɛnt fayn fɔ yu bay we i go chɛk bɔku tin dɛn, lɛk di kayn kansa we yu gɛt ɛn di patikyula jenɛtik mak dɛn (bayomakɛr) we de na yu kansa sɛl dɛn.
Aw dɛn kin gi dis tritmɛnt ɛn fɔ aw lɔng?
Dɛn kin gi imyunotɛrapi drɔgs tru wan vein, lɛk salin sɔlvushɔn, we dɛn kɔl intravenɔs (IV) injɛkshɔn. Dɛn kin gi dis tritmɛnt ɛvri 3 to 6 wik. Dis tritmɛnt kin te fɔ sɔm mɔnt to tu ia, i kin dipen pan yu sik. Yu dɔktɔ go disayd aw fɔ du di program.
Aw di imyunotɛrapi kin wok fayn?
Dis tritmɛnt stil na nyu tin. Bɔt risach dɔn sho se, mɔ fɔ pipul dɛn we gɛt triplɛ-nɛgitiv brɔst kansa, imyunotɛrapi we dɛn jɔyn wit kemotɛrapi kin mek di tɛm fɔ liv bɛtɛ pas di kemotɛrapi nɔmɔ. Dis rili prɔmis.
Naw, bɔku bɔku klinik trial dɛn de we dɛn de du ɔlsay na di wɔl. Dɛn tin ya de luk if dɛn kin yuz imyunotɛrapi fɔ ɔda kayn bɔdi kansa, ɛn if dɛn kin mek di tritmɛnt dɛn we dɔn de, bɛtɛ. So, dis tritmɛnt kin bi wan impɔtant wɛpɔn fɔ fɛt kansa tumara bambay.
Wetin na di bad tin dɛn we kin apin to pɔsin?
Jɔs lɛk ɛni tritmɛnt, imyunotɛrapi kin mek yu gɛt sayd ɛfɛkt. Bɔt dis nɔ kin afɛkt ɔlman di sem we. Sɔm pipul dɛn kin gɛt smɔl prɔblɛm nɔmɔ, ɛn ɔda pipul dɛn nɔ kin gɛt ɛni bad bad tin atɔl. Bifo yu bigin fɔ tek tritmɛnt, i rili impɔtant fɔ tɔk to yu dɔktɔ bɔt di bad tin dɛn we kin apin to yu ɛn no bɔt dɛn.
| Tayp fɔ di sayd ɛfɛkt | Karakta |
|---|---|
| Kɔmɔn sayd ɛfɛkt dɛn |
|
| Siriɔs sayd ɛfɛkt dɛn we nɔ kin apin so ɔltɛm |
Ustɛm a fɔ go to di dɔktɔ?
If yu gɛt ɛni wan pan di siriɔs sayd ɛfɛkt dɛn we wi dɔn tɔk bɔt, yu fɔ tɛl yu dɔktɔ wantɛm wantɛm . If ivin smɔl sayd ɛfɛkt nɔ bɛtɛ insay sɔm dez ɔ i rili bad, tɛl yu dɔktɔ. I impɔtant fɔ pe atɛnshɔn to ɛni chenj na yu bɔdi we yu de trit yu ɛn tɔk to yu dɔktɔ bɔt am.
Mɛsej we dɛn kin kɛr go na os
- Immunotherapy na wan advans tritmɛnt we de yuz yu yon bɔdi in imyun sistɛm fɔ fɛt brɔst kansa.
- Dis kin gi rili gud rizulyt, mɔ fɔ di kansa dɛm we at fɔ trit lɛk triplɛ-nɛgitiv.
- Dis tritmɛnt nɔ fayn fɔ ɔlman. Na yu dɔktɔ nɔmɔ go disayd if i fayn fɔ yu.
- Jɔs lɛk ɔl di tritmɛnt dɛm, sɔm kayn sayd ɛfɛkt kin de, so tɔk bɔt yu tritmɛnt ɛn ɛni sayd ɛfɛkt wit yu dɔktɔ.
- Di wok we dɛn de du fɔ mɛn kansa de go bifo ɛvride. Immunotherapy na impɔtant tin fɔ mek dɛn go bifo ɛn na nyu op fɔ di wan dɛn we gɛt kansa.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt